First Time Loading...

ATAI Life Sciences NV
NASDAQ:ATAI

Watchlist Manager
ATAI Life Sciences NV Logo
ATAI Life Sciences NV
NASDAQ:ATAI
Watchlist
Price: 1.93 USD 4.89% Market Closed
Updated: Apr 29, 2024

Intrinsic Value

ATAI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. [ Read More ]

The intrinsic value of one ATAI stock under the Base Case scenario is 2.4 USD. Compared to the current market price of 1.93 USD, ATAI Life Sciences NV is Undervalued by 20%.

Key Points:
ATAI Intrinsic Value
Base Case
2.4 USD
Undervaluation 20%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ATAI Life Sciences NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ATAI stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
ATAI Life Sciences NV

Provide an overview of the primary business activities
of ATAI Life Sciences NV.

What unique competitive advantages
does ATAI Life Sciences NV hold over its rivals?

What risks and challenges
does ATAI Life Sciences NV face in the near future?

Has there been any significant insider trading activity
in ATAI Life Sciences NV recently?

Summarize the latest earnings call
of ATAI Life Sciences NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ATAI Life Sciences NV.

Provide P/S
for ATAI Life Sciences NV.

Provide P/E
for ATAI Life Sciences NV.

Provide P/OCF
for ATAI Life Sciences NV.

Provide P/FCFE
for ATAI Life Sciences NV.

Provide P/B
for ATAI Life Sciences NV.

Provide EV/S
for ATAI Life Sciences NV.

Provide EV/GP
for ATAI Life Sciences NV.

Provide EV/EBITDA
for ATAI Life Sciences NV.

Provide EV/EBIT
for ATAI Life Sciences NV.

Provide EV/OCF
for ATAI Life Sciences NV.

Provide EV/FCFF
for ATAI Life Sciences NV.

Provide EV/IC
for ATAI Life Sciences NV.

Show me price targets
for ATAI Life Sciences NV made by professional analysts.

What are the Revenue projections
for ATAI Life Sciences NV?

How accurate were the past Revenue estimates
for ATAI Life Sciences NV?

What are the Net Income projections
for ATAI Life Sciences NV?

How accurate were the past Net Income estimates
for ATAI Life Sciences NV?

What are the EPS projections
for ATAI Life Sciences NV?

How accurate were the past EPS estimates
for ATAI Life Sciences NV?

What are the EBIT projections
for ATAI Life Sciences NV?

How accurate were the past EBIT estimates
for ATAI Life Sciences NV?

Compare the revenue forecasts
for ATAI Life Sciences NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ATAI Life Sciences NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ATAI Life Sciences NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of ATAI Life Sciences NV compared to its peers.

Compare the P/E ratios
of ATAI Life Sciences NV against its peers.

Discuss the investment returns and shareholder value creation
comparing ATAI Life Sciences NV with its peers.

Analyze the financial leverage
of ATAI Life Sciences NV compared to its main competitors.

Show all profitability ratios
for ATAI Life Sciences NV.

Provide ROE
for ATAI Life Sciences NV.

Provide ROA
for ATAI Life Sciences NV.

Provide ROIC
for ATAI Life Sciences NV.

Provide ROCE
for ATAI Life Sciences NV.

Provide Gross Margin
for ATAI Life Sciences NV.

Provide Operating Margin
for ATAI Life Sciences NV.

Provide Net Margin
for ATAI Life Sciences NV.

Provide FCF Margin
for ATAI Life Sciences NV.

Show all solvency ratios
for ATAI Life Sciences NV.

Provide D/E Ratio
for ATAI Life Sciences NV.

Provide D/A Ratio
for ATAI Life Sciences NV.

Provide Interest Coverage Ratio
for ATAI Life Sciences NV.

Provide Altman Z-Score Ratio
for ATAI Life Sciences NV.

Provide Quick Ratio
for ATAI Life Sciences NV.

Provide Current Ratio
for ATAI Life Sciences NV.

Provide Cash Ratio
for ATAI Life Sciences NV.

What is the historical Revenue growth
over the last 5 years for ATAI Life Sciences NV?

What is the historical Net Income growth
over the last 5 years for ATAI Life Sciences NV?

What is the current Free Cash Flow
of ATAI Life Sciences NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for ATAI Life Sciences NV.

Financials

Balance Sheet Decomposition
ATAI Life Sciences NV

Current Assets 185.6m
Cash & Short-Term Investments 179.3m
Receivables 4.1m
Other Current Assets 2.3m
Non-Current Assets 107.9m
Long-Term Investments 91.7m
PP&E 2.2m
Other Non-Current Assets 14m
Current Liabilities 20.1m
Accounts Payable 4.6m
Accrued Liabilities 14.8m
Other Current Liabilities 715k
Non-Current Liabilities 30.4m
Long-Term Debt 17.9m
Other Non-Current Liabilities 12.5m
Efficiency

Earnings Waterfall
ATAI Life Sciences NV

Revenue
314k USD
Operating Expenses
-125.8m USD
Operating Income
-125.5m USD
Other Expenses
85.2m USD
Net Income
-40.2m USD

Free Cash Flow Analysis
ATAI Life Sciences NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

ATAI Profitability Score
Profitability Due Diligence

ATAI Life Sciences NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Negative ROE
Negative Operating Income
25/100
Profitability
Score

ATAI Life Sciences NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

ATAI Solvency Score
Solvency Due Diligence

ATAI Life Sciences NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
55/100
Solvency
Score

ATAI Life Sciences NV's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ATAI Price Targets Summary
ATAI Life Sciences NV

Wall Street analysts forecast ATAI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATAI is 10.9 USD with a low forecast of 5.15 USD and a high forecast of 22.05 USD.

Lowest
Price Target
5.15 USD
167% Upside
Average
Price Target
10.9 USD
465% Upside
Highest
Price Target
22.05 USD
1 042% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ATAI Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ATAI Price
ATAI Life Sciences NV

1M 1M
+4%
6M 6M
+62%
1Y 1Y
-3%
3Y 3Y
-90%
5Y 5Y
-90%
10Y 10Y
-90%
Annual Price Range
1.93
52w Low
1.04
52w High
2.6
Price Metrics
Average Annual Return -63.01%
Standard Deviation of Annual Returns 3.38%
Max Drawdown -95%
Shares Statistics
Market Capitalization 320.4m USD
Shares Outstanding 166 010 000
Percentage of Shares Shorted 4.62%

ATAI Return Decomposition
Main factors of price return

What is price return decomposition?

ATAI News

Other Videos

Last Important Events
ATAI Life Sciences NV

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
ATAI Life Sciences NV

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

ATAI Life Sciences NV Logo
ATAI Life Sciences NV

Country

Germany

Industry

Pharmaceuticals

Market Cap

320.4m USD

Dividend Yield

0%

Description

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.

Contact

BERLIN
Berlin
c/o Mindspace, Krausenstrasse 9-10
+498921539035.0
https://www.atai.life/

IPO

2021-06-18

Employees

81

Officers

Founder & Chairman of the Supervisory Board
Mr. Christian Angermayer
Co-founder & CEO
Mr. Florian Brand
Co-Founder & Chief Scientific Officer
Dr. Srinivas G. Rao M.D., Ph.D.
Advisor
Mr. Stephen B. Bardin
Chief Financial Officer
Ms. Anne Johnson
Senior Vice President of Operations
Dr. Michael Raven Ph.D.
Show More
Vice President of Investment & Venture Management
Mr. Frank Stegert
Senior VP, General Counsel & Corporate Secretary
Mr. Ryan Barrett
Senior Vice President of Early Development
Dr. Glenn Short Ph.D.
Chief Business Officer
Dr. Sahil V. Kirpekar M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ATAI stock?

The intrinsic value of one ATAI stock under the Base Case scenario is 2.4 USD.

Is ATAI stock undervalued or overvalued?

Compared to the current market price of 1.93 USD, ATAI Life Sciences NV is Undervalued by 20%.